DVA Stock Analysis: DaVita HealthCare | NYSE
Medical Care Facilities | NYSE, USA | Market Cap: 15.078m USD | 12M Return: 62.3% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 185M
EPS Trend: 85.9%
Qual. Beats: 1
Rev. Trend: 99.8%
Qual. Beats: 2
Warnings
No concerns identified
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
DaVita Inc. (NYSE: DVA) is a leading U.S. provider of kidney dialysis services, primarily serving patients with chronic kidney failure, also known as end-stage renal disease (ESRD). The company operates a network of outpatient dialysis centers and provides related lab testing, hospital inpatient services, and home-based hemodialysis. Beyond core dialysis operations, DaVita offers integrated care management, disease management programs, clinical research, physician services, comprehensive kidney care, and a transplant software business. Headquartered in Denver, Colorado, the company was incorporated in 1994 and has been publicly traded since its 1995 IPO.
DaVita operates in the Health Care Services sub-industry, where dialysis is a recurring, high-revenue service driven by chronic, lifelong treatment needs. The U.S. dialysis market is essentially a duopoly, with DaVita and Fresenius Medical Care accounting for the vast majority of outpatient dialysis centers, and a large share of patient treatments is reimbursed through Medicares ESRD entitlement program.
- Medicare reimbursement rate changes pressure dialysis segment margins
- GLP-1 obesity drug adoption may slow long-term ESRD patient growth
- Integrated Kidney Care expansion drives value-based contract revenue
| Net Income: 781.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA -1.75 > 1.0 |
| NWC/Revenue: 8.64% < 20% (prev 5.62%; Δ 3.01% < -1%) |
| CFO/TA 0.12 > 3% & CFO 2.03b > Net Income 781.4m |
| Net Debt (15.1b) to EBITDA (2.70b): 5.58 < 3 |
| Current Ratio: 1.42 > 1.5 & < 3 |
| Outstanding Shares: last quarter (68.9m) vs 12m ago -15.26% < -2% |
| Gross Margin: 31.10% > 18% (prev 32.46%; Δ -1.36% > 0.5%) |
| Asset Turnover: 79.93% > 50% (prev 75.76%; Δ 4.17% > 0%) |
| Interest Coverage Ratio: 3.54 > 6 (EBIT TTM 1.98b / Interest Expense TTM 559.8m) |
| A: 0.07 (Total Current Assets 4.06b - Total Current Liabilities 2.87b) / Total Assets 17.5b |
| B: -0.01 (Retained Earnings -179.2m / Total Assets 17.5b) |
| C: 0.11 (EBIT TTM 1.98b / Avg Total Assets 17.3b) |
| D: -0.05 (Book Value of Equity -755.5m / Total Liabilities 16.5b) |
| Altman-Z'' = 1.14 = BB |
| DSRI: 1.01 (Receivables 2.98b/2.76b, Revenue 13.8b/13.0b) |
| GMI: 1.04 (GM 32.46% / 31.10%) |
| AQI: 0.99 (AQ_t 0.47 / AQ_t-1 0.48) |
| SGI: 1.07 (Revenue 13.8b / 13.0b) |
| TATA: -0.07 (NI 781.4m - CFO 2.03b) / TA 17.5b) |
| Beneish M = -2.94 (Cap -4..+1) = A |
As of July 11, 2026, the stock is trading at USD 232.80 with a total of 748,097 shares traded. Over the past week, the price has changed by -0.90%, over one month by +17.26%, over three months by +55.15% and over the past year by +62.28%.
Current recommended Stop Loss: 224.90 (which is 3.4% or 1.2 ATR below the current price).
DaVita HealthCare has received a consensus analysts rating of 3.10. Therefore, it is recommended to hold DVA.
- StrongBuy: 1
- Buy: 0
- Hold: 8
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 193.7 | -16.8% |
P/E Trailing = 22.631
P/E Forward = 15.7233
P/S = 1.0898
P/B = 21.6266
P/EG = 0.7079
Revenue TTM = 13.8b USD
EBIT TTM = 1.98b USD
EBITDA TTM = 2.70b USD
Long Term Debt = 10.5b USD (from longTermDebt, last quarter)
Short Term Debt = 544.9m USD (from shortTermDebt, last quarter)
Debt = 15.8b USD (from shortLongTermDebtTotal, last quarter) + Leases 2.59b
Net Debt = 15.1b USD (calculated: Debt 15.8b - CCE 748.7m)
Enterprise Value = 30.1b USD (15.1b + Debt 15.8b - CCE 748.7m)
Interest Coverage Ratio = 3.54 (Ebit TTM 1.98b / Interest Expense TTM 559.8m)
EV/FCF = 20.19x (Enterprise Value 30.1b / FCF TTM 1.49b)
FCF Yield = 4.95% (FCF TTM 1.49b / Enterprise Value 30.1b)
FCF Margin = 10.79% (FCF TTM 1.49b / Revenue TTM 13.8b)
Net Margin = 5.65% (Net Income TTM 781.4m / Revenue TTM 13.8b)
Gross Margin = 31.10% ((Revenue TTM 13.8b - Cost of Revenue TTM 9.53b) / Revenue TTM)
Gross Margin QoQ = 31.42% (prev 28.28%)
Tobins Q-Ratio = 1.72 (Enterprise Value 30.1b / Total Assets 17.5b)
Interest Expense / Debt = 3.54% (Interest Expense 559.8m / Debt 15.8b)
Taxrate = 21.77% (305.2m / 1.40b)
NOPAT = 1.55b (EBIT 1.98b * (1 - 21.77%))
Current Ratio = 1.42 (Total Current Assets 4.06b / Total Current Liabilities 2.87b)
Debt / Equity = -20.93 (negative equity) (Debt 15.8b / totalStockholderEquity, last quarter -755.5m)
Debt / EBITDA = 5.58 (Net Debt 15.1b / EBITDA 2.70b)
Debt / FCF = 10.09 (Net Debt 15.1b / FCF TTM 1.49b)
Total Stockholder Equity = 871.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 4.51% (Net Income 781.4m / Total Assets 17.5b)
RoE = 89.71% (Net Income TTM 781.4m / Total Stockholder Equity 871.0m)
RoCE = 17.42% (EBIT 1.98b / Capital Employed (Equity 871.0m + L.T.Debt 10.5b))
RoIC = 10.71% (NOPAT 1.55b / Invested Capital 14.5b)
WACC = 5.49% (E(15.1b)/V(30.9b) * Re(8.34%) + D(15.8b)/V(30.9b) * Rd(3.54%) * (1-Tc(0.22)))
Discount Rate = 8.34% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -76.41 | Cagr: -12.40%
[DCF] Terminal Value 73.10% ; FCFF base≈1.60b ; Y1≈1.40b ; Y5≈1.13b
[DCF] Fair Price = 48.64 (EV 18.2b - Net Debt 15.1b = Equity 3.12b / Shares 64.2m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 85.88 | EPS CAGR: 20.04% | SUE: 1.64 | # QB: 1
Revenue Correlation: 99.76 | Revenue CAGR: 5.93% | SUE: 1.38 | # QB: 2
EPS current Quarter (2026-06-30): EPS=3.84 | Chg30d=+5.94% | Revisions=+12% | Analysts=6
EPS next Quarter (2026-09-30): EPS=3.93 | Chg30d=+3.46% | Revisions=+12% | Analysts=6
EPS current Year (2026-12-31): EPS=14.80 | Chg30d=+4.79% | Revisions=+70% | GrowthEPS=+37.3% | GrowthRev=+3.7%
EPS next Year (2027-12-31): EPS=17.18 | Chg30d=+4.78% | Revisions=+50% | GrowthEPS=+16.1% | GrowthRev=+3.4%
[Analyst] Revisions Ratio: +52% (up=19, down=5)